ICOSAVAX
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candida... tes targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.
ICOSAVAX
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2017-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.icosavax.com
Total Employee:
11+
Status:
Active
Total Funding:
161 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Pyxis Oncology
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Current Advisors List
Board_member
Current Employees Featured
David Baker Co-founder @ Icosavax
Co-founder
Adam Simpson Chief Executive Officer & Co-Founder @ Icosavax
Chief Executive Officer & Co-Founder
2018-01-01
Founder
Stock Details
Investors List
Sanofi Ventures
Sanofi Ventures investment in Series B - Icosavax
Qiming Venture Partners USA
Qiming Venture Partners USA investment in Series B - Icosavax
RA Capital Management
RA Capital Management investment in Series B - Icosavax
Viking Global Investors
Viking Global Investors investment in Series B - Icosavax
Omega Funds
Omega Funds investment in Series B - Icosavax
Open Philanthropy Project
Open Philanthropy Project investment in Series B - Icosavax
Perceptive Advisors
Perceptive Advisors investment in Series B - Icosavax
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Icosavax
NanoDimension
NanoDimension investment in Series B - Icosavax
Surveyor Capital
Surveyor Capital investment in Series B - Icosavax
Official Site Inspections
http://www.icosavax.com Semrush global rank: 2.96 M Semrush visits lastest month: 5.5 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Icosavax"
Acquisition of Icosavax Completed - AstraZeneca
Feb 19, 2024 The acquisition was completed through a tender offer to purchase all outstanding shares of Icosavax for a price of $15.00 per share in cash up front, plus a non-tradable …See details»
Icosavax - Crunchbase Company Profile & Funding
Organization. Icosavax . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... (RSV), human metapneumovirus (hMPV), and severe acute respiratory …See details»
AstraZeneca to acquire Icosavax, including potential first-in-class …
Dec 12, 2023 Icosavax VLP technology VLPs are a proven technology with multiple products on the market, including vaccines for human papillomavirus and hepatitis B. 6 While currently …See details»
Icosavax, Inc. Company Profile | Seattle, WA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Icosavax, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Dec 12, 2023 Icosavax s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Its pipeline includes additional …See details»
EX-99.2 - SEC.gov
The acquisition allows our organizations to combine their expertise with the goal of discovering and developing best-in-class vaccines intended to provide long-lasting immunity to millions. As …See details»
AstraZeneca Completes Acquisition of Icosavax - PharmTech
Feb 21, 2024 The definitive acquisition agreement between the two companies was announced back in a Dec. 15, 2023 press release, when Iskra Reic, executive vice-president, Vaccines & …See details»
AstraZeneca Completes Acquisition of Icosavax - IChemE
AstraZeneca has successfully completed its acquisition of US-based clinical-stage biopharmaceutical company, Icosavax. Through this acquisition, AstraZeneca will be able to …See details»
AstraZeneca Completes Acquisition of Icosavax - BioPharm …
Feb 21, 2024 The definitive acquisition agreement between the two companies was announced back in a Dec. 15, 2023 press release, when Iskra Reic, executive vice-president, Vaccines & …See details»
Why AstraZeneca Is Buying Icosavax For $1.1 Billion - Investopedia
Dec 12, 2023 Shares of Icosavax skyrocketed over 48% in early trading Tuesday after AstraZeneca agreed to purchase the biopharma company for $1.1 billion to expand its reach …See details»
Acquisition of Icosavax Completed - AstraZeneca
Feb 19, 2024 The acquisition was completed through a tender offer to purchase all outstanding shares of Icosavax for a price of $15.00 per share in cash up front, plus a non-tradable …See details»
AstraZeneca to Acquire Icosavax in Deal Valued at ... - PharmTech
Jan 2, 2024 On Dec. 12, 2023, AstraZeneca announced a definitive agreement to acquire Icosavax, a US-based clinical stage biopharmaceutical company focused on developing …See details»
AstraZeneca to buy Icosavax for $1.1B
Today we learned that Icosavax, a Seattle-based vaccine design company born from innovative research conducted here at the Institute for Protein Design, will be acquired by AstraZeneca in …See details»
AstraZeneca to acquire Icosavax – Company Announcement
Dec 12, 2023 Adam Simpson, Chief Executive officer, Icosavax, said: "We are pleased to announce the proposed acquisition of Icosavax by AstraZeneca as we believe it offers the …See details»
Icosavax Company Profile 2024: Stock Performance & Earnings
Icosavax is headquartered in Seattle, WA. What is the size of Icosavax? Icosavax has 60 total employees. What industry is Icosavax in? Icosavax’s primary industry is Drug Discovery. Is …See details»
DEF 14A - SEC.gov
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on …See details»
Icosavax: Giving VLPs the VIP Treatment - genengnews.com
Apr 13, 2021 Icosavax emerged from stealth mode in 2019 with $51 million in Series A financing. The Series B was led by RA Capital Management. RA Capital’s founder and …See details»
AZ agrees $1.1bn deal to buy RSV jab developer Icosavax
5 days ago The $15-per-share deal is a 43% premium to Icosavax’s closing share price yesterday and values the company at around $1.1 billion, of which $800 million is payable …See details»
Icosavax - CoMotion
Icosavax went public in July 2021 and has raised more than $150 million from private investors since 2017. How it works The breakthrough technology deploys computational methods to …See details»
Icosavax - Company Profile - Tracxn
Nov 7, 2024 Icosavax ranks 10th among 314 active competitors. 101 of its competitors are funded while 71 have exited. Overall, Icosavax and its competitors have raised over $10.8B in …See details»